IL2

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

IL2 is one of 186 small molecule programs targeting Kidney Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Alopecia AreataActive, not recruiting

Multiple SclerosisActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Metastatic Prostate CancerPhase 1/Phase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Alopecia AreataPhase 3

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

IL2

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Vascepa

AAmarin Pharma Inc.

Preclinical

1 10

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Recruiting

Colorectal Cancer

NCT02919644

Clinical

Trials by Indication[1]

Alopecia Areata1 trial

TREg Activation in the Treatment of the PELADE (Alopecia Areata)

Completed·—·Phase 3·NCT02557074·44 enrolled

Metastatic Prostate Cancer1 trial

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT00283829·30 enrolled

Colorectal Cancer1 trial

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

Recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02919644·19 enrolled

Kidney Cancer1 trial

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT00582790·12 enrolled

Multiple Sclerosis1 trial

Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02424396·30 enrolled

1 more indication

Interleukin1 trial

Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant

Completed·NNantes University Hospital·Phase 1·NCT03862833·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for IL2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IL2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IL2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

IL2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Alopecia Areata1 trial

Metastatic Prostate Cancer1 trial

Colorectal Cancer1 trial

Kidney Cancer1 trial

Multiple Sclerosis1 trial

Interleukin1 trial

References

Drug Info

Quick Facts

Related News